Sphera Funds Management LTD. Buys New Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Sphera Funds Management LTD. bought a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 197,550 shares of the biotechnology company's stock, valued at approximately $3,714,000. Sphera Funds Management LTD. owned 0.16% of Arrowhead Pharmaceuticals at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. R Squared Ltd purchased a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter worth about $38,000. Van ECK Associates Corp lifted its position in shares of Arrowhead Pharmaceuticals by 72.3% in the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 1,250 shares during the period. KBC Group NV lifted its position in shares of Arrowhead Pharmaceuticals by 45.9% in the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock worth $98,000 after purchasing an additional 1,644 shares during the period. Envestnet Portfolio Solutions Inc. purchased a new position in Arrowhead Pharmaceuticals during the 4th quarter valued at about $190,000. Finally, First Citizens Bank & Trust Co. purchased a new position in Arrowhead Pharmaceuticals during the 4th quarter valued at about $205,000. 62.61% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, CEO Christopher Richard Anzalone sold 51,425 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $15.07, for a total value of $774,974.75. Following the completion of the sale, the chief executive officer now directly owns 4,062,377 shares in the company, valued at $61,220,021.39. The trade was a 1.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold 275,880 shares of company stock worth $4,034,037 over the last three months. 4.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Citigroup lowered their price target on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a research report on Tuesday, May 13th. HC Wainwright reissued a "buy" rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. Royal Bank of Canada reissued an "outperform" rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Chardan Capital reissued a "buy" rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 13th. Finally, B. Riley reissued a "buy" rating and set a $38.00 price target (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $42.13.

Arrowhead Pharmaceuticals Stock Up 0.2%

Arrowhead Pharmaceuticals stock traded up $0.03 during trading hours on Monday, hitting $15.74. The stock had a trading volume of 1,897,041 shares, compared to its average volume of 1,485,386. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27. The stock has a market capitalization of $2.17 billion, a P/E ratio of -3.04 and a beta of 0.89. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $30.41. The stock's 50-day moving average price is $13.30 and its 200-day moving average price is $17.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $2.81. The firm had revenue of $542.71 million during the quarter, compared to analysts' expectations of $116.27 million. During the same period last year, the firm posted ($1.02) earnings per share. Equities research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.